Hereditary spastic paraplegia: Journey to a treatment

In 2016, Darius Ebrahimi-Fakhari, MD, PhD, then a neurology fellow at Boston Kids’s Hospital, met two little ladies with spasticity and decreased muscle tone of their legs, which affected their strolling. Each ladies, Robbie Edwards and Molly Duffy, had been recognized with hereditary spastic paraplegia (HSP), which includes a bunch of greater than 80 genetic circumstances. Untreated, the spasticity and weak spot slowly progress, usually requiring a wheelchair by age 10, and are sometimes accompanied by international developmental delays and seizures.

Robbie and Molly had the identical uncommon subtype of HSP, attributable to mutations within the gene for HSP sort 47, or SPG47. The one different circumstances of SPG47 then identified had been from 4 households within the Center East. Other than interventions like occupational, bodily, and speech remedy, there have been no therapies.

“There have been no analysis or scientific trials seeking to deal with SPG47,” says Robbie’s mom, Kasey Edwards, who had fashioned a nonprofit along with the Duffy household. “It grew to become clear that we would want to provoke analysis ourselves.”

The Translational Neuroscience Center at Boston Kids’s requested Ebrahimi-Fakhari to analyze the foundation explanation for SPG47 and maybe discover a remedy. As a PhD scholar, he had studied autophagy, a mobile recycling course of that’s identified to be disrupted by mutations within the SPG47 gene.

Almost a decade later, Ebrahimi-Fakhari’s lab has found a potential drug that will work for a number of subtypes of HSP, together with SPG47. A number of gene therapies are additionally in scientific improvement for different subtypes.

Kick-starting HSP analysis

Early on, Edwards and her husband spent hours poring over analysis articles, making an attempt to study as a lot as doable. “I purchased Genetics for Dummies, Neuropsychiatry for Dummies, Neurology for Dummies,” Edwards says. “I used to be happening rabbit holes.”

They started contacting the authors of among the articles in addition to labs and biotech corporations. In 2017, the nonprofit convened a global assembly of scientists and physicians engaged on HSP, held at Boston Kids’s.

“We determined that so as to sort out this illness, we would have liked first to search out extra sufferers,” says Ebrahimi-Fakhari.

He began by sending 500 emails to his colleagues and others all over the world, asking whether or not anybody had seen a affected person with SPG47. In the present day, Boston Kids’s runs the primary and solely longitudinal natural history study for childhood-onset HSP, a registry with almost 600 sufferers, together with about 100 with SPG47.

SPG47 is now a part of a subtype of HSP generally known as AP-4 HSP — which the team first described in detail in 2020 — along with the associated circumstances SPG50, SPG51, and SPG52. Boston Kids’s quickly launched the HSP Genomic Sequencing Initiative, which has now expanded right into a nationwide community of facilities devoted to the scientific care of and analysis for HSP: The Spastic Paraplegia Centers of Excellence Research Network (SP-CERN). In October 2025, Ebrahimi-Fakhari’s lab and Boston Kids’s had been awarded $8.4 million in NIH funding to assist and increase the SP-CERN’s work in HSP analysis.

Increasing the HSP registry

The registry continues to develop. Edwards helped add an vital group of sufferers: Noting that some individuals with HSP have members of the family recognized with cerebral palsy, she linked Ebrahimi-Fakhari and his colleagues with the Worldwide Cerebral Palsy Genetics Consortium. Subsequently, Siddharth Srivastava, MD, and Maya Chopra, MBBS, FRACP, at Boston Kids’s launched a genetic examine of sufferers with a cerebral palsy prognosis.

Whereas CP is usually attributed to beginning trauma, the examine discovered that one in four patients had an underlying genetic diagnosis — usually, an HSP-related mutation.

“Our objective is to incorporate AP-4 genes in genetic testing for kids presumed to have cerebral palsy,” says Ebrahimi-Fakhari. “Except the kid has an affected sibling, the everyday affected person journey is three to 4 years to a prognosis.”

The subsequent problem was to develop a remedy.

Fixing a caught protein

Ebrahimi-Fakhari’s lab, with Mustafa Sahin, MD, PhD, and others, had found that AP-4 HSP is attributable to a deficiency in AP-4, a fancy of 4 molecules that assist transport a protein vital to neurologic perform throughout the cell. This protein, ATG9A, is concerned in autophagy, enabling neurons to interrupt down and reuse previous cell elements.

Every type of AP-4 HSP is attributable to a mutation in considered one of AP-4’s 4 elements, disabling the complicated. Consequently, ATG9A will get caught and accumulates within the flawed place.

“That is obvious on microscopy,” says Ebrahimi-Fakhari. “It’s a black-and-white form of distinction.”

Early efforts centered on creating gene therapies. One remedy, correcting the SPG50 gene, additionally supported by the Boston Kids’s group, is now in a scientific trial sponsored by the UT Southwestern Medical Heart. A second, geared toward correcting SPG47, will likely be submitted for a scientific trial to be sponsored by Boston Kids’s.

Ebrahimi-Fakhari, nevertheless, needed a remedy that will be accessible to a bigger variety of kids, probably an oral medicine. By Boston Children’s Technology and Innovation Office, his lab partnered with Astellas Pharma, Inc.

As described in 2024 in Nature Communications, the group examined about 29,000 compounds in pores and skin cells or stem-cell-derived neurons constituted of sufferers with AP-4 HSP. Utilizing imaging, they might spot which cells had been being mounted, Ebrahimi-Fakhari says.

“We requested: What molecule can get these caught proteins to the place they should be?”

Shifting towards remedy

From an preliminary group of 16 compounds that restored correct transport of ATG9A, one compound dubbed BCH-HSP-C0-1 made it by extra testing, together with exams to make sure it really works in neurons constituted of kids with SPG47.

“This small molecule works for all 4 subtypes of AP-4 HSP, a key benefit over gene therapies, which right one subtype at a time,” notes Ebrahimi-Fakhari. “Now, we have to see if it really works in a dwell mouse mannequin.”

If it does, the subsequent step can be to use to the FDA to do a scientific trial. Whereas some signs of AP-4 HSP, like spasticity, are seemingly irreversible, Ebrahimi-Fakhari thinks there’s a risk that restoring ATG9A transport might stop illness development.

Edwards is happy about these new developments.

“To have a compound recognized that may tackle the signs is a possible dream come true,” says Edwards. She hopes Robbie, now a sassy, sociable 10-year-old who loves music and enjoying UNO, would have the ability to take part within the trial.

“Darius and his colleagues have been so form and affected person in permitting me to ask questions and bounce off concepts and construct my data base,” she says. “In the event that they hadn’t, I won’t have tried to study as a lot as I’ve.”

For inquiries in regards to the know-how, contact Sabrina Kamran, PhD, on the Expertise and Innovation Growth Workplace.

Be taught extra in regards to the HSP Sequencing initiative and the SP/CERN network.